Tidal Investments LLC acquired a new position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 37,534 shares of the company’s stock, valued at approximately $3,716,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Blueline Advisors LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the 4th quarter valued at $41,000. Accent Capital Management LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth about $42,000. Root Financial Partners LLC grew its position in shares of iShares U.S. Pharmaceuticals ETF by 88.9% in the 4th quarter. Root Financial Partners LLC now owns 510 shares of the company’s stock worth $43,000 after buying an additional 240 shares during the last quarter. Trust Co. of Vermont bought a new stake in iShares U.S. Pharmaceuticals ETF in the second quarter valued at $60,000. Finally, Integrated Wealth Concepts LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth $75,000.
iShares U.S. Pharmaceuticals ETF Stock Up 0.7%
NYSEARCA IHE opened at $101.81 on Tuesday. iShares U.S. Pharmaceuticals ETF has a twelve month low of $69.02 and a twelve month high of $108.66. The firm has a market capitalization of $1.63 billion, a PE ratio of 17.75 and a beta of 0.49. The stock’s 50 day moving average is $102.91 and its 200 day moving average is $94.42.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
